eFFECTOR Therapeutics, Inc. (EFTR)
EFTR Stock Price Chart
Explore eFFECTOR Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze EFTR price movements and trends.
EFTR Company Profile
Discover essential business fundamentals and corporate details for eFFECTOR Therapeutics, Inc. (EFTR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
1 Mar 2021
Employees
14.00
Website
https://effector.comCEO
Craig R. Jalbert CIRA
Description
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
EFTR Financial Timeline
Browse a chronological timeline of eFFECTOR Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 27 Oct 2025
Earnings released on 4 Jun 2025
Earnings released on 30 May 2025
Earnings released on 28 Feb 2025
Earnings released on 14 Nov 2024
Earnings released on 28 Aug 2024
Earnings released on 9 May 2024
EPS came in at -$2.16 surpassing the estimated -$2.17 by +0.46%.
Earnings released on 25 Mar 2024
EPS came in at -$3.42 falling short of the estimated -$2.73 by -25.27%, while revenue for the quarter reached $162.00K .
Stock split effective on 12 Jan 2024
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 Nov 2023
EPS came in at -$3.25 matching the estimated -$3.25.
Earnings released on 8 Aug 2023
EPS came in at -$4.25 surpassing the estimated -$4.75 by +10.53%.
Earnings released on 9 May 2023
EPS came in at -$6.00 falling short of the estimated -$5.50 by -9.09%.
Earnings released on 8 Mar 2023
EPS came in at -$5.50 falling short of the estimated -$4.50 by -22.22%, while revenue for the quarter reached $674.00K , beating expectations by +2.12%.
Earnings released on 7 Nov 2022
EPS came in at -$5.75 surpassing the estimated -$6.75 by +14.81%, while revenue for the quarter reached $867.00K , beating expectations by +8.00%.
Earnings released on 9 Aug 2022
EPS came in at -$4.25 surpassing the estimated -$4.50 by +5.56%, while revenue for the quarter reached $2.01M , beating expectations by +378.81%.
Earnings released on 10 May 2022
EPS came in at $1.75 surpassing the estimated -$8.00 by +121.88%.
Earnings released on 16 Mar 2022
EPS came in at $11.00 surpassing the estimated -$6.25 by +276.00%, while revenue for the quarter reached $1.43M , beating expectations by +1.33K%.
Earnings released on 8 Nov 2021
EPS came in at $0.42 surpassing the estimated -$0.20 by +310.00%, while revenue for the quarter reached $427.00K .
Earnings released on 31 Aug 2021
EPS came in at -$6.15 , while revenue for the quarter reached $692.00K .
Earnings released on 3 Jun 2021
EPS came in at -$11.00 .
Earnings released on 29 Mar 2021
EPS came in at -$0.66 , while revenue for the quarter reached $42.00K .
Earnings released on 30 Sept 2020
EPS came in at -$12.71 , while revenue for the quarter reached $574.00K .
EFTR Stock Performance
Access detailed EFTR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.